Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV

Antiviral Therapy

Volumn 9, Issue 1, 2004, Pages 3-12

  Parkin, Neil T ^a   Schapiro, Jonathan M ^b,c  

^a MONOGRAM BIOSCIENCES   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT FAILURE; VIRUS DIAGNOSIS; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TYPING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV-1; HIV-2; HUMANS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 1542376702     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S & Korber B. HIV-1 nomenclature proposal. Science 2000; 288:55-56.
2. Hu DJ, Dondero TJ, Rayfield MA, George JR, Schochetman G, Jaffe HW, Luo CC, Kalish ML, Weniger BG, Pau CP, Schable CA & Curran JW. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. Journal of the American Medical Association 1996; 275:210-216.
3. Peeters M & Sharp PM. Genetic diversity of HIV-1: the moving target. AIDS 2000; 14(Suppl. 3):S129-S140.
4. Korber B, Theiler J & Wolinsky S. Limitations of a molecular clock applied to considerations of the origin of HIV-1. Science 1998; 280:1868-1871.
5. McCutchan FE, Salminen MO, Carr JK & Burke DS. HIV-1 genetic diversity. AIDS 1996; 10(Suppl. 3):S13-S20.
6. Gao F, Robertson DL, Carruthers CD, Morrison SG, Jian B, Chen Y, Barre-Sinoussi F, Girard M, Srinivasan A, Abimiku AG, Shaw GM, Sharp PM & Hahn BH. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. Journal of Virology 1998; 72:5680-5698.
7. Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Munoz-Fernandez M & Babiker A. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. Journal of Infectious Diseases 2002; 186:617-625.
8. Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, de Sa CA, Eyer-Silva WA, Sion FS, Passioni LF, Menezes JA, Calazans AR & Tanuri A. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 2000; 275:107-115.
9. Alaeus A, Lidman K, Bjorkman A, Giesecke J & Albert J. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 1999; 13:901-907.
10. Amornkul PN, Tansuphasawadikul S, Limpakarnjanarat K, Likanonsakul S, Young N, Eampokalap B, Kaewkungwal J, Naiwatanakul T, Von Bargen J, Hu DJ & Mastro TD. Clinical disease associated with HIV-1 subtype B′ and E infection among 2104 patients in Thailand. AIDS 1999; 13:1963-1969.
11. Del Amo J, Petruckevitch A, Phillips A, Johnson AM, Stephenson J, Desmond N, Hanscheid T, Low N, Newell A, Obasi A, Paine K, Pym A, Theodore CM & De Cock KM. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998; 12:1203-1209.
12. Galai N, Kalinkovich A, Burstein R, Vlahov D & Bentwich Z. African HIV-1 subtype C and rate of progression among Ethiopian immigrants in Israel. Lancet 1997; 349:180-181.
13. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, Lyagoba F, Hamilton L, Biryahwaho B & Whitworth J. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15:293-299.
14. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J, Gilks C & Whitworth J. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. Journal of Infectious Diseases 2002; 185:1244-1250.
15. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, Woodcock SA, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, I ND, Essex ME & S MB. Human immunodeficiency virus type 1 subtypes differ in disease progression. Journal of Infectious Diseases 1999; 179:68-73.
16. Artenstein AW, Coppola J, Brown AE, Carr JK, Sanders-Buell E, Galbarini E, Mascola JR, VanCott TC, Schonbrood P, McCutchan FE et al. Multiple introductions of HIV-1 subtype E into the western hemisphere. Lancet 1995; 346:1197-1198.
17. Irwin KL, Pau CP, Lupo D, Pienazek D, Luo CC, Olivo N, Rayfield M, Hu DJ, Weber JT, Respess RA, Janssen R, Minor P & Ernst J. Presence of human immunodeficiency virus (HIV) type 1 subtype A infection in a New York community with high HIV prevalence: a sentinel site for monitoring HIV genetic diversity in North America. Centers for Disease Control and Prevention-Bronx Lebanon HIV Serosurvey Team. Journal of Infectious Diseases 1997; 176:1629-1633.
18. Identification of HIV-1 group O infection - Los Angeles County, California, 1996. Morbidity & Mortality Weekly Report 1996; 45:561-565.
19. Alaeus A, Leitner T, Lidman K & Albert J. Most HIV-1 genetic subtypes have entered Sweden. AIDS 1997; 11:199-202.
20. Arnold C, Barlow KL, Parry JV & Clewley JP. At least five HIV-1 sequence subtypes (A, B, C, D, A/E) occur in England. AIDS Research & Human Retroviruses 1995; 11:427-429.
21. Balotta C, Facchi G, Violin M, Van Dooren S, Cozzi-Lepri A, Forbici F, Bertoli A, Riva C, Senese D, Caramello P, Carnevale G, Rizzardini G, Cremonini L, Monno L, Rezza G, Perno CF, Ippolito G, d'Arminio-Monforte A, Vandamme AM & Moroni M. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. Journal of Acquired Immune Deficiency Syndromes 2001; 27:499-505.
22. Boni J, Pyra H, Gebhardt M, Perrin L, Burgisser P, Matter L, Fierz W, Erb P, Piffaretti JC, Minder E, Grob P, Burckhardt JJ, Zwahlen M & Schupbach J. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. Journal of Acquired Immune Deficiency Syndromes 1999; 22:174-179.
23. Brodine SK, Mascola JR, Weiss PJ, Ito SI, Porter KR, Artenstein AW, Garland FC, McCutchan FE & Burke DS. Detection of diverse HIV-1 genetic subtypes in the USA. Lancet 1995; 346:1198-1199.
24. Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, Barile A, VanCott TC, Vahey MT, McCutchan FE, Birx DL, Richman DD & Mascola JR. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 serocon-version. Annals of Internal Medicine 1999; 131:502-506.
25. Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, Tamminga CL, Stephan KT, Aronson NE, Fraser SL, Wallace MR, Wegner SA, Mascola JR & McCutchan FE. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 2003; 17:2521-2527.
26. Gao F, Yue L, Hill SC, Robertson DL, Graves AH, Saag MS, Shaw GM, Sharp PM & Hahn BH. HIV-1 sequence subtype D in the United States. AIDS Research & Human Retroviruses 1994; 10:625-627.
27. Weidle PJ, Ganea CE, Irwin KL, Pieniazek D, McGowan JP, Olivo N, Ramos A, Schable C, Lal RB, Holmberg SD & Ernst JA. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. Journal of Infectious Diseases 2000; 181:470-475.
28. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, Telenti A, Battegay M, Veuthey AL, Bru JP, Rickenbach M, Hirschel B & Perrin L. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-2292.
29. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288:222-235.
30. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R & Larder BA. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671-1677.
31. Paxinos EE, Werhane H, Whitcomb JM & Petropoulos CJ. Enhanced phenotypic drug susceptibility assay for HIV-1 subtypes: A, B, C, D, F, and G. IAS Conference on HIV Pathogenesis & Treatment. Buenos Aires, Argentina, July 8-11 2001. Abstract 560.
32. Brindeiro PA, Brindeiro RM, Mortensen C, Hertogs K, De Vroey V, Rubini NP, Sion FS, De Sa CA, Machado DM, Succi RC & Tanuri A. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. Journal of Clinical Microbiology 2002; 40:4512-4519.
33. Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, Respess R, Hertogs K, Larder B, Ochola D, Mermin J, Samb B & Lackritz E. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative - Uganda. AIDS 2003; 17(Suppl. 3):S39-S48.
34. Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, Van Laethem K, Van Vaerenbergh K, Snoeck J, Van Wijngaerden E, De Clercq E, Van Ranst M & Vandamme AM. Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. Journal of Acquired Immune Deficiency Syndromes 2001; 28:254-258.
35. Shafer RW, Chuang TK, Hsu P, White CB & Katzenstein DA. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 sero-converters in Zimbabwe. AIDS Research & Human Retroviruses 1999; 15:65-69.
36. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J & Delaporte E. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. Journal of Clinical Microbiology 2000; 38:3919-3925.
37. Cane PA, de Ruiter A, Rice P, Wiselka M, Fox R & Pillay D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. Journal of Clinical Microbiology 2001; 39:2652-2654.
38. Kantor R, Zijenah LS, Shafer RW, Mutetwa S, Johnston E, Lloyd R, von Lieven A, Israelski D & Katzenstein DA. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Research & Human Retroviruses 2002; 18:1407-1413.
39. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M & Wainberg MA. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrobial Agents & Chemotherapy 2002; 46:2087-2094.
40. Pillay C, Bredell H, McIntyre J, Gray G & Morris L. HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Research & Human Retroviruses 2002; 18:605-610.
41. Handema R, Terunuma H, Kasolo F, Kasai H, Sichone M, Yamashita A, Deng X, Mulundu G, Ichiyama K, Munkanta M, Yokota T, Wakasugi N, Tezuka F, Yamamoto N & Ito M. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Research & Human Retroviruses 2003; 19:151-160.
42. Kantor R & Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Review 2003; 5:25-35.
43. Morris L, Pillay C, Chezzi C, Lupondwana P, Ntsala M, Levin L, Venter F, Martinson N, Gray G & McIntyre J. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS 2003; 17:1698-1700.
44. Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V, Lal R & Dondero T. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000; 14:1489-1495.
45. Gonzales MJ, Machekano RN & Shafer RW. Human immunodeficiency virus type 1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. Journal of Infectious Diseases 2001; 184:998-1006.
46. Caride E, Hertogs K, Larder B, Brindeiro R, Machado E, De Sa CAM, Eyer-Silva WA, Sion FS, Passioni LFC, Menezes JA, Calazans AR & Tanuri A. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus Type 1 found in Brazilian patients failing HAART. Virus Genes 2001; 23:193-202.
47. Mracna M, Becker-Pergola G, Dileanis J, Guay LA, Cunningham S, Jackson JB & Eshleman SH. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. Journal of Clinical Microbiology 2001; 39:4323-4327.
48. Jagodzinski LL, Cooley JD, Weber M & Michael NL. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. Journal of Clinical Microbiology 2003; 41:998-1003.
49. Beddows S, Galpin S, Kazmi SH, Ashraf A, Johargy A, Frater AJ, White N, Braganza R, Clarke J, McClure M & Weber JN. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. Journal of Medical Virology 2003; 70:337-342.
50. Descamps D, Collin G, Letourneur F, Apetrei C, Damond G, Loussert-Ajaka I, Simon F, Saragosti S & Brun-Vezinet F. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. Journal of Virology 1997; 71:8893-8898.
51. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, Burke M, Gottesman G, Istomin V, Levi I, Maayan S, Shahar E & Schapiro JM. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 2001; 15:1453-1460.
52. Tanuri A, Vicente AC, Otsuki K, Ramos CA, Ferreira OC Jr, Schechter M, Janini LM, Pieniazek D & Rayfield MA. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrobial Agents & Chemotherapy 1999; 43:253-258.
53. Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, Simon F & Brun-Vezinet F. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. Journal of Virology 1998; 72:3534-3538.
54. Descamps D, Apetrei C, Collin G, Damond F, Simon F & Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12:1109-1111.
55. Palmer S, Alaeus A, Albert J & Cox S. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Research & Human Retroviruses 1998; 14:157-162.
56. Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ & Pellegrin JL. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002; 16:1331-1340.
57. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E & Rode RA. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Journal of Virology 2001; 75:7462-7469.
58. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CAB, Leonard JM, Norbeck DW & Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766.
59. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S & Boucher CA. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13:2349-2359.
60. Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR & Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrobial Agents & Chemotherapy 1998; 42:2637-2644.
61. Kebba A, Atwine D, Mwebaze R, Kityo C, Nakityo R & Peter M. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. AIDS Research & Human Retroviruses 2002; 18:1181-1187.
62. Velazquez-Campoy A, Todd MJ, Vega S & Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proceedings of the National Academy of Sciences, USA 2001; 98:6062-6067.
63. Velazquez-Campoy A, Vega S & Freire E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 2002; 41:8613-8619.
64. Grossman Z, Istomin V, Averbuch D, Lorber M, Risenberg K, Levy I, Chowers M, Bentwich Z, Burke M, Bar Yaacov N, Mendelson E, Ram D, Maayan S & Shapiro JM. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2003. In Press.
65. Roman F, Gonzalez D, Lambert C, Deroo S, Fischer A, Baurith T, Staub T, Boulme R, Arendt V, Schneider F, Hemmer R & Schmit JC. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. Journal of Acquired Immune Deficiency Syndromes 2003; 33:134-139.
66. Xu L, Hue S, Taylor S, Ratcliffe D, Workman JA, Jackson S, Cane PA & Pillay D. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 2002; 16:1684-1686.
67. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K & Sugiura W. Patterns of point mutations associated with anti-retroviral drug treatment failure in CRF01-AE (subtype E) infection differ from subtype B infection. Journal of Acquired Immune Deficiency Syndromes 2003; 33:336-342.
68. Gomes P, Diogo I, Goncalves MF, Carvalho P, Cabanas J, Lobo MC & Camacho R. Different pathways to nelfinavir resistance in HIV-1 subtypes B and G. 9th Conference on Retroviruses & Opportunistic Infections. Seattle, Wash., USA, February 24-28 2002. Abstract 46.
69. Grossman Z, Paxinos E, Auerbuch D, Maayan S, Parkin N, Engelhard D, Lorber M, Kedem E, Mileguir F, Vardinon N, Bentwich Z, Petropoulos C & Schapiro JM. D30N is not the preferred resistance pathway in subtype C patients treated with nelfinavir. Antiviral Therapy 2002; 7(Suppl. 1):S30.
70. Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ & Parkin NT. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. Journal of Virology 2000; 74:4414-4419.
71. Lam E & Parkin NT. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation. Clinical Infectious Diseases 2003; 37:1273-1274.
72. Gallego O, Corral A, de Mendoza C & Soriano V. Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir. Clinical Infectious Diseases 2002; 34:1288-1289.
73. Resch W, Ziermann R, Parkin N, Gamarnik A & Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. Journal of Virology 2002; 76:8659-8666.
74. Zachary KC, Hanna GJ & D'Aquila RT. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. Clinical Infectious Diseases 2001; 33:2075-2077.
75. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M & Wainberg MA. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-F5.
76. Hightower M & Kallas EG. Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review. Brazilian Journal of Infectious Diseases 2003; 7:7-15.
77. Reeves JD & Doms RW. Human immunodeficiency virus type 2. Journal of General Virology 2002; 83:1253-1265.
78. Schim van der Loeff MF & Aaby P. Towards a better understanding of the epidemiology of HIV-2. AIDS 1999; 13(Suppl. A):S69-S84.
79. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM & Hahn BH. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397:436-441.
80. Shanmugam V, Switzer WM, Nkengasong JN, Garcia-Lerma G, Green TA, Ekpini E, Sassan-Morokro M, Antunes F, Manshino K, Soriano V, Wiktor SZ & Heneine W. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. Journal of Acquired Immune Deficiency Syndromes 2000; 24:257-263.
81. Khabbaz RF, Rowe T, Murphey-Corb M, Heneine WM, Schable CA, George JR, Pau CP, Parekh BS, Lairmore MD, Curran JW et al. Simian immunodeficiency virus needlestick accident in a laboratory worker. Lancet 1992; 340:271-273.
82. Khabbaz RF, Heneine W, George JR, Parekh B, Rowe T, Woods T, Switzer WM, McClure HM, Murphey-Corb M & Folks TM. Brief report: infection of a laboratory worker with simian immunodeficiency virus. New England Journal of Medicine 1994; 330:172-177.
83. Uberla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proceedings of the National Academy of Sciences, USA 1995; 92:8210-8214.
84. Reimann KA, Li JT, Veazey R, Halloran M, Park IW, Karlsson GB, Sodroski J & Letvin NL. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. Journal of Virology 1996; 70:6922-6928.
85. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E & Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral Therapy 2004; 9:57-65.
86. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA & Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. Journal of Molecular Biology 1994; 243:369-387.
87. Koup RA, Merluzzi VJ, Hargrave KD, Adams J, Grozinger K, Eckner RJ & Sullivan JL. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. Journal of Infectious Diseases 1991; 163:966-970.
88. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E & Vandamme AM. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 1999; 13:1477-1483.
89. Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, Ainsworth J, Choudhury A, Daniels RS, El-Gadi S, Fakoya A, Moyle G, Oxford J, Tedder R, O'Shea S, de Ruiter A & Breuer J. Antiretroviral therapy for HIV-2 infected patients. Journal of Infection 2001; 42:126-133.
90. Haubrich R, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, Leibowitz M, Hwang J, Seefried E, McCutchan JA, Hellmann N, Richman D & CCTG. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antiviral Therapy 2001; 6(Suppl. 1):63.
91. van der Ende ME, Guillon C, Boers PH, Ly TD, Gruters RA, Osterhaus AD & Schutten M. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. Journal of Acquired Immune Deficiency Syndromes 2000; 25:11-18.
92. Giuffre AC, Higgins J, Buckheit RW Jr & North TW. Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrobial Agents & Chemotherapy 2003; 47:1756-1759.
93. Maguire M, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, Elston R, Yeo J, Randall S, Xu F, Parker H, May J & Snowden W. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrobial Agents & Chemotherapy 2002; 46:731-738.
94. Whitcomb JM, Huang W, Fransen S, Wrin MT, Paxinos E, Toma J, Greenberg M, Sista P, Melby T, Matthews T, DeMasi R, Heilek-Snyder G, Cammack N, Hellmann N & Petropoulos CJ. Analysis of baseline enfuvirtide (T20) susceptibility and co-receptor tropism in two Phase III study populations. 10th Conference on Retroviruses & Opportunistic Infections. Boston, Mass., USA, February 10-14 2003. Abstract 557.
95. Ross L, Parkin N, Chappey C, Tisdale M & Elston R. HIV clinical isolates containing mutations representative of those selected after first line failure with unboosted GW433908 remain sensitive to other protease inhibitors. Antiviral Therapy 2003; 8(Suppl. 1):S22.
96. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ & Lin PF. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrobial Agents & Chemotherapy 2000; 44:2319-2326.
97. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E & Doms RW. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proceedings of the National Academy of Sciences, USA 2002; 99:16249-16254.
98. Descamps D, Damond F, Matheron S, Collin G, Campa P, Foiny P, Delarue S, Pueyo S, Chêne G & Brun-Vézinet F. High frequency of selection of the Q151M mutation in HIV-2-infected patients receiving nucleoside reverse transcriptase inhibitor-containing regimen. Antiviral Therapy 2003; 8(Suppl. 1):S162.
99. Colson P, Henry M, Tivoli N, Gallais H, Gastaut JA, Moreau J & Tamalet C. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southern France. Antiviral Therapy 2003; 8(Suppl. 1):S161.
100. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W & Nkengasong JN. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003; 17(Suppl. 3):S49-S54.
101. van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD & Schutten M. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003; 17(Suppl. 3):S55-S61.
102. Brandin E, Lindborg L, Gyllensten K, Brostrom C, Hagberg L, Gisslen M, Tuvesson B, Blaxhult A & Albert J. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Research & Human Retroviruses 2003; 19:543-550.
103. Murry JP, Higgins J, Matthews TB, Huang VY, Van Rompay KK, Pedersen NC & North TW. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. Journal of Virology 2003; 77:1120-1130.
104. Parkin N, Hellmann N, Whitcomb JM, Kiss L, Chappey C & Petropoulos CJ. Natural variation of drug susceptibility among wild type HIV-1. Antimicrobial Agents & Chemotherapy 2004. In Press.
105. D'Aquila RT, Shapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW & Richman DD. Drug resistance mutations in HIV-1. Topics in HIV Medicine 2003; 11:92-96.
106. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J & Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 2003; 31:298-303.